Ameriprise Financial Inc. Has $426,000 Stock Position in Alphatec Holdings, Inc. (NASDAQ:ATEC)

Ameriprise Financial Inc. decreased its holdings in Alphatec Holdings, Inc. (NASDAQ:ATEC - Free Report) by 80.3% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 46,354 shares of the medical technology company's stock after selling 189,132 shares during the quarter. Ameriprise Financial Inc.'s holdings in Alphatec were worth $426,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently bought and sold shares of ATEC. American Century Companies Inc. raised its position in Alphatec by 36.5% in the fourth quarter. American Century Companies Inc. now owns 4,989,057 shares of the medical technology company's stock worth $45,800,000 after acquiring an additional 1,334,780 shares in the last quarter. Marshall Wace LLP increased its holdings in shares of Alphatec by 139.2% in the fourth quarter. Marshall Wace LLP now owns 1,773,246 shares of the medical technology company's stock valued at $16,278,000 after buying an additional 1,032,070 shares in the last quarter. Emerald Advisers LLC increased its holdings in shares of Alphatec by 112.4% in the fourth quarter. Emerald Advisers LLC now owns 1,456,033 shares of the medical technology company's stock valued at $13,366,000 after buying an additional 770,586 shares in the last quarter. Tudor Investment Corp ET AL grew its holdings in shares of Alphatec by 295.4% in the 4th quarter. Tudor Investment Corp ET AL now owns 585,865 shares of the medical technology company's stock worth $5,378,000 after acquiring an additional 437,690 shares during the last quarter. Finally, Emerald Mutual Fund Advisers Trust grew its holdings in shares of Alphatec by 94.3% in the 4th quarter. Emerald Mutual Fund Advisers Trust now owns 841,643 shares of the medical technology company's stock worth $7,726,000 after acquiring an additional 408,516 shares during the last quarter. Institutional investors own 66.35% of the company's stock.

Insider Buying and Selling at Alphatec

In related news, COO Scott Lish sold 55,375 shares of the company's stock in a transaction on Monday, May 19th. The shares were sold at an average price of $13.00, for a total transaction of $719,875.00. Following the completion of the sale, the chief operating officer now directly owns 771,645 shares of the company's stock, valued at approximately $10,031,385. This represents a 6.70% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 20.90% of the company's stock.

Analysts Set New Price Targets

ATEC has been the topic of several analyst reports. Needham & Company LLC reissued a "buy" rating and issued a $16.00 target price on shares of Alphatec in a research report on Friday, May 2nd. Piper Sandler reiterated an "overweight" rating and set a $15.00 price objective (up from $13.00) on shares of Alphatec in a research report on Friday, May 2nd. Wall Street Zen upgraded Alphatec from a "sell" rating to a "hold" rating in a report on Friday, February 28th. Finally, HC Wainwright reiterated a "buy" rating and set a $20.00 price target on shares of Alphatec in a report on Monday, April 14th. Two investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $17.89.

Alphatec Stock Up 2.3%

Shares of NASDAQ:ATEC traded up $0.29 during midday trading on Friday, hitting $12.73. 1,186,832 shares of the stock were exchanged, compared to its average volume of 2,039,310. The company has a market capitalization of $1.86 billion, a PE ratio of -9.95 and a beta of 1.10. Alphatec Holdings, Inc. has a 52-week low of $4.88 and a 52-week high of $13.14. The company has a debt-to-equity ratio of 30.21, a quick ratio of 1.15 and a current ratio of 2.32. The business's fifty day simple moving average is $11.47 and its two-hundred day simple moving average is $10.74.

Alphatec (NASDAQ:ATEC - Get Free Report) last posted its quarterly earnings results on Thursday, May 1st. The medical technology company reported ($0.35) earnings per share for the quarter, missing analysts' consensus estimates of ($0.12) by ($0.23). The firm had revenue of $169.18 million for the quarter, compared to analysts' expectations of $167.57 million. Alphatec had a negative return on equity of 541.39% and a negative net margin of 31.06%. The firm's revenue for the quarter was up 22.2% on a year-over-year basis. During the same period last year, the business earned ($0.34) earnings per share. As a group, research analysts predict that Alphatec Holdings, Inc. will post -1.08 earnings per share for the current fiscal year.

Alphatec Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.